Noxopharm White Paper

NOXOPHARM L IMITED White Paper 8 Veyonda® – oncology program overview The NOX clinical trial program provides a pipeline of indications designed to maximise the value of Veyonda while de-risking the portfolio. The focus is on the treatment of cancer and the use of Veyonda to boost the effectiveness of 4 primary cancer therapies: • External beam radiotherapy • Radioligand therapy • Chemotherapy • Checkpoint inhibitor therapy in what we call our 4-pillars oncology program. The 4-pillars oncology program is not self-limiting, and other combination treatments will be considered as the opportunities present. Study CEP-1 CEP-2 DARRT-1 DARRT-2 LuPIN IONIC Status Completed Active Completed Active Completed Active Patients 19 40 25 100 56 30 Target Multiple tumour types Sarcoma End-stage prostate cancer End-stage prostate, breast and lung cancer End-stage prostate cancer Multiple tumour types Therapy Veyonda® + chemotherapy Veyonda® + chemotherapy Veyonda® + low dose external beam radiotherapy Veyonda® + low dose external beam radiotherapy Veyonda® + internal radiotherapy 177 Lutetium- PSMA-617* Veyonda® + immuno- oncology therapy (Opdivo®)** * 177 Lutetium-PSMA-617 is owned by Novartis ** Opdivo (nivolumab) is owned by Bristol Myers Squibb Chemotherapy Enhancement Program (CEP) Radiotherapy Enhancement Program (DARRT) Combination with immune check point inhibitors (IONIC) Veyonda® Oncology Clinical Development Overview